- Home
- Publications
- Publication Search
- Publication Details
Title
Enhancing global access to cancer medicines
Authors
Keywords
-
Journal
CA-A CANCER JOURNAL FOR CLINICIANS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-02-19
DOI
10.3322/caac.21597
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Real-world studies no substitute for RCTs in establishing efficacy
- (2019) Hertzel C Gerstein et al. LANCET
- Modernizing Clinical Trials for Patients With Cancer
- (2019) Norman E. Sharpless et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cancer statistics for African Americans, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer treatment and survivorship statistics, 2019
- (2019) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- (2019) Helena M Earl et al. LANCET
- 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
- (2019) Xavier Pivot et al. LANCET
- Availability of anticancer medicines in public and private sectors, and their affordability by low, middle and high-income class patients in Pakistan
- (2018) Muhammad Rehan Sarwar et al. BMC CANCER
- The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment
- (2018) Pricivel M. Carrera et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching
- (2018) Paul Declerck et al. CLINICAL THERAPEUTICS
- Trajectories of Injectable Cancer Drug Costs After Launch in the United States
- (2018) Noa Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Achieving better cancer intelligence for global cancer control
- (2018) Richard Sullivan LANCET
- Improving pathology and laboratory medicine in low-income and middle-income countries: roadmap to solutions
- (2018) Shahin Sayed et al. LANCET
- Delivering modern, high-quality, affordable pathology and laboratory medicine to low-income and middle-income countries: a call to action
- (2018) Susan Horton et al. LANCET
- Offline: Can the Global Fund survive?
- (2018) Richard Horton LANCET
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Rationale, Opportunities, and Reality of Biosimilar Medications
- (2018) Gary H. Lyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- The importance of greater speed in drug development for advanced malignancies
- (2018) David J. Stewart et al. Cancer Medicine
- Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2018) Heikki Joensuu et al. JAMA Oncology
- 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
- (2018) P Conte et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Biosimilars in oncology and inflammatory diseases: current and future considerations for clinicians in Latin America
- (2018) Morton Scheinberg et al. mAbs
- A global accountability mechanism for access to essential medicines
- (2018) Mariângela Simão et al. LANCET
- Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2018) Gregory A Roth et al. LANCET
- Best practices in scaling digital health in low and middle income countries
- (2018) Alain B. Labrique et al. Globalization and Health
- Expanding global access to essential medicines: investment priorities for sustainably strengthening medical product regulatory systems
- (2018) Lukas Roth et al. Globalization and Health
- Real-world Data for Clinical Evidence Generation in Oncology
- (2017) Sean Khozin et al. JNCI-Journal of the National Cancer Institute
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- (2017) David Cameron et al. LANCET
- Essential medicines for universal health coverage
- (2017) Veronika J Wirtz et al. LANCET
- Cancer control in Africa: infrastructure, not philanthropy
- (2017) The Lancet Oncology LANCET ONCOLOGY
- First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication
- (2017) Steven Lemery et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
- (2017) Lais Osmani et al. SEMINARS IN CANCER BIOLOGY
- Integrating mHealth at point of care in low- and middle-income settings: the system perspective
- (2017) Lee Wallis et al. Global Health Action
- Real-world Data for Clinical Evidence Generation in Oncology
- (2017) Sean Khozin et al. JNCI-Journal of the National Cancer Institute
- Cancer Drugs: An International Comparison of Postlicensing Price Inflation
- (2017) Philip Savage et al. Journal of Oncology Practice
- ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe
- (2016) N. Cherny et al. ANNALS OF ONCOLOGY
- A Comparative Study Between Smartphone-Based Microscopy and Conventional Light Microscopy in 1021 Dermatopathology Specimens
- (2016) Richard R. Jahan-Tigh et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Essential medicines for cancer: WHO recommendations and national priorities
- (2016) Jane Robertson et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- “Threshold-crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?
- (2016) H-G Eichler et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Cross-comparison of cancer drug approvals at three international regulatory agencies
- (2016) N. Samuel et al. Current Oncology
- Raising the Barriers to Access to Medicines in the Developing World - The Relentless Push for Data Exclusivity
- (2016) Lisa Diependaele et al. Developing World Bioethics
- Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes
- (2016) Lawrence N. Shulman et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2016) Ben Y. Durkee et al. JOURNAL OF CLINICAL ONCOLOGY
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
- (2016) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Postmarket policy considerations for biosimilar oncology drugs
- (2016) Matthew J Renwick et al. LANCET ONCOLOGY
- Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study
- (2016) Sabine Vogler et al. LANCET ONCOLOGY
- Actual costs of cancer drugs in 15 European countries
- (2016) Wim H van Harten et al. LANCET ONCOLOGY
- Generic oncology drugs: are they all safe?
- (2016) Y Tony Yang et al. LANCET ONCOLOGY
- Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data
- (2016) Mark D. Danese et al. MEDICAL CARE
- Real-World Evidence — What Is It and What Can It Tell Us?
- (2016) Rachel E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expanding access to high-cost medicines through the E2 access program in Thailand: effects on utilisation, health outcomes and cost using an interrupted time-series analysis
- (2016) Rosarin Sruamsiri et al. BMJ Open
- Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment
- (2016) Andrew Hill et al. BMJ Open
- Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)
- (2015) D. Mavroudis et al. ANNALS OF ONCOLOGY
- HER2 expression status in diverse cancers: review of results from 37,992 patients
- (2015) Min Yan et al. CANCER AND METASTASIS REVIEWS
- IMPLICATIONS OF GLOBAL PRICING POLICIES ON ACCESS TO INNOVATIVE DRUGS: THE CASE OF TRASTUZUMAB IN SEVEN LATIN AMERICAN COUNTRIES
- (2015) Andres Pichon-Riviere et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
- (2015) Sara M. Tolaney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831
- (2014) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
- (2014) D. Kazandjian et al. ONCOLOGIST
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial
- (2013) Aron Goldhirsch et al. LANCET
- Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab: Does Time Really Matter?
- (2013) S. M. Swain ONCOLOGIST
- Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
- (2012) Gustavo Ismael et al. LANCET ONCOLOGY
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer
- (2011) Dennis Slamon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
- (2009) D. Milojkovic et al. CLINICAL CANCER RESEARCH
- Fluorouracil, Epirubicin, and Cyclophosphamide With Either Docetaxel or Vinorelbine, With or Without Trastuzumab, As Adjuvant Treatments of Breast Cancer: Final Results of the FinHer Trial
- (2009) Heikki Joensuu et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started